Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors
| Autor: | Ricci, C., Pusceddu, S., Prinzi, N., Tafuto, S., Ibrahim, T., Filice, A., Brizzi, M. P., Panzuto, F., Baldari, S., Grana, C. M., Campana, D., Davi, M. V., Giuffrida, D., Zatelli, M. C., Partelli, S., Razzore, P., Marconcini, R., Massironi, S., Gelsomino, F., Faggiano, A., Giannetta, E., Bajetta, E., Grimaldi, F., Cives, M., Cirillo, F., Perfetti, V., Corti, F., Giacomelli, L., Porcu, L., Di Maio, M., Seregni, E., Maccauro, M., Lastoria, S., Bongiovanni, A., Versari, A., Persano, I., Rinzivillo, M., Pignata, S. A., Rocca, P. A., Lamberti, G., Cingarlini, S., Puliafito, I., Ambrosio, M. R., Zanata, I., Bracigliano, A., Severi, S., Spada, F., Andreasi, V., Modica, R., Scalorbi, F., Milione, M., Sabella, G., Coppa, J., Casadei, R., Di Bartolomeo, M., Falconi, M., De Braud, F. |
|---|---|
| Přispěvatelé: | Pusceddu, Sara, Prinzi, Natalie, Tafuto, Salvatore, Ibrahim, Toni, Filice, Angelina, Brizzi, Maria Pia, Panzuto, Francesco, Baldari, Sergio, Grana, Chiara M., Campana, Davide, Davì, Maria Vittoria, Giuffrida, Dario, Zatelli, Maria Chiara, Partelli, Stefano, Razzore, Paola, Marconcini, Riccardo, Massironi, Sara, Gelsomino, Fabio, Faggiano, Antongiulio, Giannetta, Elisa, Bajetta, Emilio, Grimaldi, Franco, Cives, Mauro, Cirillo, Fernando, Perfetti, Vittorio, Corti, Francesca, Ricci, Claudio, Giacomelli, Luca, Porcu, Luca, Di Maio, Massimo, Seregni, Ettore, Maccauro, Marco, Lastoria, Secondo, Bongiovanni, Alberto, Versari, Annibale, Persano, Irene, Rinzivillo, Maria, Pignata, Salvatore Antonio, Rocca, Paola Anna, Lamberti, Giuseppe, Cingarlini, Sara, Puliafito, Ivana, Ambrosio, Maria Rosaria, Zanata, Isabella, Bracigliano, Alessandra, Severi, Stefano, Spada, Francesca, Andreasi, Valentina, Modica, Roberta, Scalorbi, Federica, Milione, Massimo, Sabella, Giovanna, Coppa, Jorgelina, Casadei, Riccardo, Di Bartolomeo, Maria, Falconi, Massimo, de Braud, Filippo, Grana, Chiara M, Davi, Maria Vittoria |
| Rok vydání: | 2022 |
| Předmět: |
Male
Radiotherapy Receptors Peptide General Medicine sequence Middle Aged peptide receptors radionuclide therapy everolimus chemotherapy Progression-Free Survival NO Peptide Receptor Radionuclide Therapy Pancreatic Neoplasms Neuroendocrine Tumors receptor radionuclide therapy enteropancreatic neuroendocrine tumors progression free survival Receptors Peptide Humans Female LS4_3 neuroendocrine tumors sequence everolimus Retrospective Studies |
| Zdroj: | JAMA network open. 5(2) |
| ISSN: | 2574-3805 |
| Popis: | Importance: Data about the optimal timing for the initiation of peptide receptor radionuclide therapy (PRRT) for advanced, well-differentiated enteropancreatic neuroendocrine tumors are lacking. Objective: To evaluate the association of upfront PRRT vs upfront chemotherapy or targeted therapy with progression-free survival (PFS) among patients with advanced enteropancreatic neuroendocrine tumors who experienced disease progression after treatment with somatostatin analogues (SSAs). Design, setting, and participants: This retrospective, multicenter cohort study analyzed the clinical records from 25 Italian oncology centers for patients aged 18 years or older who had unresectable, locally advanced or metastatic, well-differentiated, grades 1 to 3 enteropancreatic neuroendocrine tumors and received either PRRT or chemotherapy or targeted therapy after experiencing disease progression after treatment with SSAs between January 24, 2000, and July 1, 2020. Propensity score matching was done to minimize the selection bias. Exposures: Upfront PRRT or upfront chemotherapy or targeted therapy. Main outcomes and measures: The main outcome was the difference in PFS among patients who received upfront PRRT vs among those who received upfront chemotherapy or targeted therapy. A secondary outcome was the difference in overall survival between these groups. Hazard ratios (HRs) were fitted in a multivariable Cox proportional hazards regression model to adjust for relevant factors associated with PFS and were corrected for interaction with these factors. Results: Of 508 evaluated patients (mean ([SD] age, 55.7 [0.5] years; 278 [54.7%] were male), 329 (64.8%) received upfront PRRT and 179 (35.2%) received upfront chemotherapy or targeted therapy. The matched group included 222 patients (124 [55.9%] male; mean [SD] age, 56.1 [0.8] years), with 111 in each treatment group. Median PFS was longer in the PRRT group than in the chemotherapy or targeted therapy group in the unmatched (2.5 years [95% CI, 2.3-3.0 years] vs 0.7 years [95% CI, 0.5-1.0 years]; HR, 0.35 [95% CI, 0.28-0.44; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|